🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

4 big analyst picks: Sherwin-Williams a buy at Jefferies on firming housing market

Published 2023-05-24, 06:30 a/m
© Reuters.
SHW
-
OC
-
QTRX
-
CCCS
-

Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: upgrades at Sherwin-Williams, CCC Intelligent Solutions, Owens Corning, and Quanterix.

InvestingPro subscribers got this news before anyone else. Start your 7-day trial to get on board.

Sherwin-Williams upgraded at Jefferies

Jefferies upgraded Sherwin-Williams (NYSE:SHW) to Buy from Hold and raised its price target to $275.00 from $240.00.

The firm believes the risk/reward balance is more favorable for Sherwin-Williams, particularly on a relative basis. With the housing cycle turning and policy shocks that derail a recovery likely having a much sharper impact on industrial and consumer goods companies, Sherwin-Williams is expected to benefit from share gains, margin improvements, and disciplined capital allocation, leading to above-trend EPS growth in 2025-2027.

InvestingPro | Outsmart the Market

CCC Intelligent Solutions upgraded to Outperform, a steady vertical SaaS story with an AI catalyst

Evercore ISI upgraded CCC Intelligent Solutions (NASDAQ:CCCS) to Outperform from In Line and raised its price target to $13.00 from $11.00 as it offers a favorable risk/reward for investors seeking a SMID-cap company in a competitive market.

The firm believes that the combination of potential revenue upside as well as approximately 100bps in annual operating margin expansion offers up a compelling risk/reward for those looking for an ‘under the radar’ vertical SaaS idea.

2 more upgrades

Barclays upgraded Owens Corning (NYSE:OC) to Overweight from Equalweight and raised its price target to $135.00 from $113.00. Shares are up 1% pre-market today.

Goldman Sachs upgraded Quanterix (NASDAQ:QTRX) to Buy from Neutral with a price target of $27.00. Shares gained more than 9% yesterday and are trading around 2% higher pre-market today.

According to the firm, Quanterix has improved its cost base, offering potential for greater operating leverage. Additionally, the company is well-positioned in the early stages of blood-based Alzheimer's diagnostics and other neurological conditions.

Jump on the biggest news for your portfolio amid a barrage of market headlines: Always be the first to know with InvestingPro.

Start your free 7-day trial now.

InvestingPro | Be The First To Know

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.